Monopar Therapeutics 10-Q quarterly reports

Monopar Therapeutics Inc. files its Q2 2026 Form 10-Q, detailing progress on ALXN1840 for Wilson disease, including near completion of its NDA rolling submission, and advancements in its radiopharmaceutical pipeline.

Monopar Therapeutics reports Q1 2026 results, detailing progress in its ALXN1840 and radiopharmaceutical programs, alongside financial performance and future funding outlook.

Monopar Therapeutics significantly boosts its cash reserves by $91.9 million and reports clinical progress across its Wilson disease and radiopharmaceutical oncology pipeline.

Monopar Therapeutics Inc. reported an increased net loss for Q2 2025, while advancing its ALXN1840 Wilson disease program towards an NDA filing and progressing its radiopharmaceutical pipeline.

Monopar Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its Wilson disease and radiopharmaceutical programs.

Monopar Therapeutics reported its Q3 2024 financial results, highlighted progress in its radiopharmaceutical programs, and announced the in-licensing of a late-stage Wilson disease drug candidate.

Monopar Therapeutics is focusing on its radiopharmaceutical programs, winding down other programs, and reported a net loss of $3.36 million for the first half of 2024.

Monopar Therapeutics is focusing on its radiopharmaceutical programs, reporting a net loss of $1.64 million for the first quarter of 2024, while advancing its lead candidate into a Phase 1 clinical trial.